Assenagon Asset Management S.A. Boosts Holdings in Boston Scientific Corporation $BSX

Assenagon Asset Management S.A. lifted its stake in Boston Scientific Corporation (NYSE:BSX) by 133.6% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,057,936 shares of the medical equipment provider’s stock after purchasing an additional 5,751,760 shares during the period. Boston Scientific accounts for approximately 1.0% of Assenagon Asset Management S.A.’s holdings, making the stock its 15th largest position. Assenagon Asset Management S.A.’s holdings in Boston Scientific were worth $631,135,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Brighton Jones LLC raised its stake in shares of Boston Scientific by 0.8% in the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock worth $2,445,000 after buying an additional 226 shares during the period. FWL Investment Management LLC purchased a new position in shares of Boston Scientific during the 2nd quarter valued at about $26,000. Main Street Financial Solutions LLC grew its stake in shares of Boston Scientific by 35.3% during the 2nd quarter. Main Street Financial Solutions LLC now owns 7,556 shares of the medical equipment provider’s stock valued at $812,000 after acquiring an additional 1,971 shares during the period. Ieq Capital LLC grew its stake in shares of Boston Scientific by 97.0% during the 2nd quarter. Ieq Capital LLC now owns 123,592 shares of the medical equipment provider’s stock valued at $13,275,000 after acquiring an additional 60,860 shares during the period. Finally, HUB Investment Partners LLC increased its holdings in Boston Scientific by 56.2% in the 2nd quarter. HUB Investment Partners LLC now owns 7,102 shares of the medical equipment provider’s stock worth $763,000 after acquiring an additional 2,556 shares in the last quarter. 89.07% of the stock is owned by institutional investors.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific rose as the broader market dipped, suggesting investors are still willing to buy the shares despite volatility and recent weakness. Boston Scientific (BSX) Gains As Market Dips: What You Should Know
• Positive Sentiment: Piper Sandler maintained an Overweight rating, and even after cutting its price target to $65 from $90, it still implies meaningful upside from current levels. Piper Sandler Maintains Overweight Rating for Boston Scientific (BSX)
• Positive Sentiment: Analyst coverage remains broadly constructive, with reports noting Boston Scientific has an average “Moderate Buy” rating on Wall Street. Boston Scientific Corporation (NYSE:BSX) Receives Average Rating of “Moderate Buy” from Analysts
• Neutral Sentiment: Truist reportedly lowered its target price, but the headline alone does not indicate a rating downgrade, so the market impact looks mixed rather than clearly negative. Truist Cuts Boston Scientific (BSX) ’s Target as Doctors Change How They Use Its Heart Device
• Negative Sentiment: Unusual options activity showed a sharp increase in put buying, which can signal that some traders are positioning for downside or hedging risk.
• Negative Sentiment: Jim Cramer’s comments that “this whole cohort is just too hard to own” reinforce a cautious view on the medtech group and may add to investor hesitation. Jim Cramer on Boston Scientific: “This Whole Cohort Is Just Too Hard to Own”

Boston Scientific Price Performance

NYSE:BSX opened at $45.65 on Wednesday. The firm has a market capitalization of $67.85 billion, a price-to-earnings ratio of 19.10, a PEG ratio of 0.85 and a beta of 0.56. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22. The business has a 50 day simple moving average of $54.04 and a 200-day simple moving average of $72.07. Boston Scientific Corporation has a 1 year low of $44.05 and a 1 year high of $109.50.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The firm had revenue of $5.20 billion for the quarter, compared to the consensus estimate of $5.19 billion. During the same quarter in the previous year, the company posted $0.75 EPS. The company’s revenue for the quarter was up 11.6% compared to the same quarter last year. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Equities analysts forecast that Boston Scientific Corporation will post 3.36 EPS for the current year.

Boston Scientific announced that its Board of Directors has initiated a share buyback plan on Monday, May 18th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the medical equipment provider to purchase up to 6.4% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s management believes its shares are undervalued.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on BSX shares. Oppenheimer set a $90.00 price target on shares of Boston Scientific in a report on Thursday, April 23rd. Mizuho dropped their price target on Boston Scientific from $115.00 to $90.00 and set an “outperform” rating for the company in a research note on Monday, April 13th. Stifel Nicolaus set a $75.00 price objective on shares of Boston Scientific in a report on Wednesday, May 27th. Wall Street Zen cut shares of Boston Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, March 28th. Finally, Leerink Partners dropped their price target on Boston Scientific from $87.00 to $74.00 and set an “outperform” rating for the company in a research note on Thursday, May 28th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Boston Scientific presently has an average rating of “Moderate Buy” and an average target price of $85.08.

Insiders Place Their Bets

In other Boston Scientific news, Director Cheryl Pegus bought 1,770 shares of the company’s stock in a transaction on Wednesday, May 20th. The stock was acquired at an average price of $56.49 per share, for a total transaction of $99,987.30. Following the completion of the transaction, the director directly owned 1,770 shares of the company’s stock, valued at approximately $99,987.30. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Edward J. Ludwig purchased 3,580 shares of the firm’s stock in a transaction that occurred on Wednesday, May 20th. The shares were acquired at an average cost of $56.68 per share, with a total value of $202,914.40. Following the completion of the purchase, the director directly owned 25,359 shares in the company, valued at $1,437,348.12. The trade was a 16.44% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought a total of 9,800 shares of company stock valued at $554,012 over the last 90 days. Insiders own 0.34% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.